NCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
Clinical Trials
12 trialsNCT06419946 2026-04-13
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Recruiting
NCT05095376 2026-04-03
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05904119 2026-02-17
LEGATO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT01290939 2021-02-15
Bevacizumab and Lomustine for Recurrent GBM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00295815 2019-09-12
Enzastaurin Versus Lomustine in Glioblastoma
Eli Lilly and Company
Phase 3 Completed
NCT01149109 2017-06-14
CeTeG
University Hospital, Bonn
Phase 3 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00052455 2013-12-18
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003788 2013-11-06
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00068952 2008-04-01
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Pfizer
Phase 3 Completed